MRSN Overview
Upcoming Projects (MRSN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (MRSN)
-
A look at Mersana Therapeutics' first-in-class NaPi2b-targeting Antibody Drug Conjugate, UpRi (upifitamab rilsodotin) with an ovarian cancer specialist
Ticker: MRSN
Executed On: Jun 22, 2023 at 10:00 AM EDT -
Discussing Antibody Drug Conjugates for ovarian cancer with a focus on Immunogen's ELAHERE in advance of the upcoming MIRASOL confirmatory trial data & Mersana's Upifitamab Rilsodotin (UpRi)
Tickers: IMGN, MRSN, STRO
Executed On: Mar 17, 2023 at 01:00 PM EDT
Upcoming & Overdue Catalysts (MRSN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (MRSN)
-
Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer Antibody-Drug Conjugates and XMT-1522
Tickers: MRSN, TKD.F
Announcement Date: Feb 03, 2016
